VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -94.28% | -84.64% | 6.48% | -11.15% | 37.78% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.23% | -73.46% | -69.29% | -75.82% | -66.15% |
| Change in Net Operating Assets | 381.51% | 500.70% | 267.35% | -172.47% | -84.91% |
| Cash from Operations | -75.18% | -65.18% | 11.42% | -45.71% | -6.78% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.62% | -- | -- | -171.38% | -6,235,500.00% |
| Cash from Investing | 120.43% | -- | -- | -171.38% | -6,235,500.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -6,500.00% | 95.74% | 40.00% | 69.23% | 33.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.16% | 95.74% | 40.00% | 98.16% | 39,641.83% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.23% | -156.51% | 209.99% | -1,562.59% | 429.68% |